FDA Requires New Labeling for AntidepressantsOctober 4th 2021
The labeling for selective serotonin reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake Inhibitors (SSNRIs) now must include information about sexual side effects in the warning and precautions and patient counseling sections.
FDA’s New Warning Includes Xeljanz and other JAK InhibitorsSeptember 3rd 2021
The FDA’s review of the JAK inhibitor class concluded there is an increased risk of serious heart-related events such as heart attack or stroke, cancer, blood clots, and death with these arthritis and ulcerative colitis medicines.
Hospital Pharmacists Concerned About Actemra ShortageSeptember 2nd 2021
Pharmacists are referring patients elsewhere or are shifting patients who were using the IV form to the subcutaneous injection. The NIH has also recommended using Kevzara as an alternative where there are shortages of Actemra.
Study: Statins Reduce Death Rate in Patients with COVID-19July 20th 2021
This research sought to understand the relationship of prior medication exposure, existing health conditions, and COVID-19 outcomes using data from the American Heart Association’s COVID-19 Cardiovascular Disease Registry.